Compared to the PCOS group, the levels of p-Smad2 and Smad4 significantly decreased in the Rha-treated group and the Met-treated group (P < 0.05 and P < 0.01, respectively). This evidence concerns the gene SMAD2 and polycystic ovary syndrome.